ARS Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense
ARS Pharmaceuticals, Inc. (SPRY) reported Share-based Payment Arrangement, Expense of $14.53 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2025-03-20
- ARS Pharmaceuticals, Inc. share-based payment arrangement, expense for the quarter ending 2024-12-31 was $4.26M, a 87.14% increase year-over-year.
- ARS Pharmaceuticals, Inc. share-based payment arrangement, expense for the quarter ending 2024-09-30 was $3.59M, a 37.64% increase year-over-year.
- ARS Pharmaceuticals, Inc. share-based payment arrangement, expense for the quarter ending 2024-06-30 was $3.37M, a 60.39% increase year-over-year.
- ARS Pharmaceuticals, Inc. share-based payment arrangement, expense for the quarter ending 2024-03-31 was $3.31M, a 47.33% increase year-over-year.
- ARS Pharmaceuticals, Inc. share-based payment arrangement, expense for fiscal 2024 was $14.53M, a 57.38% increase from fiscal 2023.
- ARS Pharmaceuticals, Inc. share-based payment arrangement, expense for fiscal 2023 was $9.23M, a 58.05% increase from fiscal 2022.
- ARS Pharmaceuticals, Inc. share-based payment arrangement, expense for fiscal 2022 was $5.84M, a 106.54% increase from fiscal 2021.
- ARS Pharmaceuticals, Inc. share-based payment arrangement, expense for fiscal 2021 was $2.83M, a 7.16% increase from fiscal 2020.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 9 month as first filed | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | $4.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $7.85M derived: sum of 2 quarters · filed 2025-03-20 | $11.22M derived: sum of 3 quarters · filed 2025-03-20 | $14.53M 10-K · filed 2025-03-20 | ||||
| 2024-09-30 | $3.59M 10-Q · filed 2024-11-13 | $6.96M derived: sum of 2 quarters · filed 2024-11-13 | $10.27M 10-Q · filed 2024-11-13 | $12.55M derived: sum of 4 quarters · filed 2025-03-20 | ||||
| 2024-06-30 | $3.37M 10-Q · filed 2024-08-06 | $6.68M 10-Q · filed 2024-08-06 | $8.96M derived: sum of 3 quarters · filed 2025-03-20 | $11.57M derived: sum of 4 quarters · filed 2025-03-20 | ||||
| 2024-03-31 | $3.31M 10-Q · filed 2024-05-09 | $5.59M derived: sum of 2 quarters · filed 2025-03-20 | $8.20M derived: sum of 3 quarters · filed 2025-03-20 | $10.30M derived: sum of 4 quarters · filed 2025-03-20 | ||||
| 2023-12-31 | $2.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $4.89M derived: sum of 2 quarters · filed 2025-03-20 | $6.99M derived: sum of 3 quarters · filed 2025-03-20 | $9.23M 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | $2.61M 10-Q · filed 2024-11-13 | $4.71M derived: sum of 2 quarters · filed 2024-11-13 | $6.96M 10-Q · filed 2024-11-13 | $11.72M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $2.10M 10-Q · filed 2024-08-06 | $4.35M 10-Q · filed 2024-08-06 | $9.11M derived: sum of 3 quarters · filed 2024-08-06 | $9.57M derived: sum of 4 quarters · filed 2024-08-06 | ||||
| 2023-03-31 | $2.25M 10-Q · filed 2024-05-09 | $7.01M derived: sum of 2 quarters · filed 2024-05-09 | $7.47M derived: sum of 3 quarters · filed 2024-05-09 | $7.83M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $4.76M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $5.22M derived: sum of 2 quarters · filed 2024-03-21 | $5.58M derived: sum of 3 quarters · filed 2024-03-21 | $5.84M 10-K · filed 2024-03-21 | ||||
| 2022-09-30 | $460.00K 10-Q · filed 2023-11-09 | $5.04M 10-Q · filed 2022-11-02 | $816.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.08M 10-Q · filed 2023-11-09 | $15.13M 10-Q · filed 2022-11-02 | -$10.13M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $356.00K 10-Q · filed 2023-08-10 | $5.14M 10-Q · filed 2022-08-11 | $620.00K 10-Q · filed 2023-08-10 | $10.09M 10-Q · filed 2022-08-11 | -$10.59M derived: sum of 3 quarters · filed 2023-08-10 | -$5.57M derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | $264.00K 10-Q · filed 2023-05-15 | $4.95M 10-Q · filed 2022-05-12 | -$10.94M derived: sum of 2 quarters · filed 2023-05-15 | -$5.92M derived: sum of 3 quarters · filed 2023-05-15 | -$1.19M derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | -$11.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$6.19M derived: sum of 2 quarters · filed 2023-03-23 | -$1.46M derived: sum of 3 quarters · filed 2023-03-23 | $2.83M 10-K · filed 2023-03-23 | $19.19M 10-K · filed 2022-03-31 | |||
| 2021-09-30 | $5.02M 10-Q · filed 2022-11-02 | $9.75M derived: sum of 2 quarters · filed 2022-11-02 | $14.03M 10-Q · filed 2022-11-02 | $16.31M derived: sum of 4 quarters · filed 2022-11-02 | ||||
| 2021-06-30 | $4.73M 10-Q · filed 2022-08-11 | $9.02M 10-Q · filed 2022-08-11 | $11.29M derived: sum of 3 quarters · filed 2022-08-11 | $11.48M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $4.29M 10-Q · filed 2022-05-12 | $6.56M derived: sum of 2 quarters · filed 2022-05-12 | $6.75M derived: sum of 3 quarters · filed 2022-05-12 | $6.88M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $2.46M derived: sum of 2 quarters · filed 2022-03-31 | $2.59M derived: sum of 3 quarters · filed 2022-03-31 | $2.64M 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | $191.00K 10-Q · filed 2021-11-10 | $319.00K derived: sum of 2 quarters · filed 2021-11-10 | $366.00K 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $128.00K 10-Q · filed 2021-08-12 | $175.00K 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | $47.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |